Myriad, AstraZeneca expand CDx collaboration
SALT LAKE CITY—In an effort to provide companion diagnostics for the Phase III clinical development program of olaparib, Myriad Genetics Inc. and AstraZeneca have begun an expanded, nonexclusive global collaboration agreement. AstraZeneca is currently developing olaparib for the treatment of various tumor types, including BRCA-mutated breast and ovarian cancers. Myriad will build a new lab within its Salt Lake City facility per U.S. Food and Drug Administration regulations for companion diagnostic devices.
"We are excited to be expanding our companion diagnostic collaboration with AstraZeneca," Peter D. Meldrum, president and CEO of Myriad, commented in a statement. "We are working together to transform the future of personalized medicine and to deliver significant value for patients and the healthcare system, and we are committed to being a leader in companion diagnostics."